In 381 patients with relapsed polymyalgia rheumatica on a 24-week prednisone taper, secukinumab 300 mg or 150 mg gave sustained week-52 remission in 41.2% and 40.6% vs 20.4% with placebo (P<0.001), with lower glucocorticoid doses; serious adverse events were similar.
RCTn = 381
Stone et al. Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica